drug
KEYTRUDA
updated 6mo agoby Merck Sharp & Dohme LLC
community read0 votes
🐶 often sniffed alongside
top 8- drugpembrolizumab515 co-mentions · 131 sources
- tagApproval512 co-mentions · 128 sources
- drugKEYTRUDA QLEX269 co-mentions · 131 sources
- drugCancer Program256 co-mentions · 128 sources
- drug(berahyaluronidase alfa + pembrolizumab)10 co-mentions · 5 sources
- tagGlioblastoma2 co-mentions · 1 sources
- tagNeurology1 co-mentions · 1 sources
- drugaxelopran1 co-mentions · 1 sources
all catalysts(0)
nothing on the calendar yet
Trials studying KEYTRUDA
- phase3Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
- phase3Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)
- phase3A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- phase3A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- phase3A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- phase2A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
- phase2ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation
- phase2A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
News(10)
- Sellas marks 9-month survival benefit in late-stage leukemia vaccine studySellas Life Sciences’ cancer vaccine for acute myeloid leukemia has passed a phase 3 test with a more than nine-month improvement in overall survival.fiercebiotech · 1d ago
- Summit shares fall as FDA rejects closely watched PD-1/VEGF drugThe FDA refused to overlook ivonescimab’s failure to initially extend survival in a form of lung cancer, setting back Summit’s first chance to win a U.S. approval.biopharma_dive · 1d ago
- Summit's PD-1xVEGF rejected by FDA in lung cancerThe FDA has denied an approval for Summit Therapeutics’ ivonescimab to treat EGFR-mutated non-small cell lung cancer, blocking the drug’s entry to the U.S. after it became available in China in 2024.biospace · 2d ago
- FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF classThe FDA has issued a complete response letter to Summit Therapeutics, derailing the immediate U.S. launch of a drug class that many industry heavyweights believe could eventually dethrone Merck & C…fiercebiotech · 4d ago
- BMS R&D head to depart amid restructureBristol Myers Squibb is combining all research and development efforts under one leader as pressure rises to replenish its pipeline.biospace · 5d ago
- BioNTech pays $205M for FDA voucher to speed up ‘late-stage oncology pipeline’BioNTech has agreed to pay $205 million to purchase an FDA priority review voucher to support a future filing of a drug in its “late-stage oncology pipeline.” Fierce breaks down which candidate is…fiercebiotech · 6d ago
- Bayer wins first-in-class FDA nod for blood thinner, setting stage for BMS-J&J rivalBayer’s Sunharbo has secured the first FDA approval of its class, establishing a regulatory pathway for other factor XIa inhibitors, such as Bristol Myers Squibb and Johnson and Johnson’s milvexian.biospace · 7d ago
- AbCellera becomes latest biotech to abandon dream of developing OX40 drugAbCellera has become the latest drug developer to abandon its attempts to crack the OX40 code.fiercebiotech · 7d ago
- FDA orders class-wide GLP-1 label update to include potential risk for rare eye diseaseTwelve marketed drugs, including Eli Lilly’s and Novo’s weight loss mega-blockbusters, will require a label change under the new FDA update.biospace · 8d ago
- Could we see 10 Chinese Big Pharmas within a decade? Some CEOs think soFor executives at many of the Chinese drug developers who spoke to Fierce, the real prize is a seat at the Big Pharma table. In recent years, this objective has moved from a vague aspiration to a c…fiercebiotech · 10d ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that